European Commission Approves Clovis’ Rubraca for Recurrent Ovarian Cancer

European Commission Approves Clovis’ Rubraca for Recurrent Ovarian Cancer
The European Commission recently authorized Rubraca (rucaparib) for the treatment for women with recurrent BRCA-mutant ovarian cancer with relapsed or progressive disease. The recent approval is for the maintenance treatment of recurrent epithelial, ovarian, fallopian tube or primary peritoneal cancer in women who are in a complete or partial response to platinum-based chemotherapy. “Rucaparib provides a unique

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *